WINNIPEG, Manitoba, Feb. 15, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that Harry Glorikian has joined its Business Advisory Board. Mr. Glorikian has over 30 years of private and public company success in the biomedical and life sciences industries. He is recognized as a global innovator with high-profile consulting, executive and board experience and a passion for data driven medical diagnostics.
Mr. Glorikian’s notable recent experience includes roles as Entrepreneur in Residence to GE Ventures – New Business Creation Group and as a member of the board of directors of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company) and Evidation Health (a digital health startup launched with support from GE Ventures). He is also a co-founder and an advisory board member of DrawBridge Health (a diagnostics startup launched with support from GE Ventures).
Previously Mr. Glorikian co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.
“With the addition of Harry Glorikian to the Business Advisory Board, 3DS has gained tremendous insight into the development and commercialization of cutting-edge medical diagnostics,” noted Jason Flowerday, CEO of 3DS. “Mr. Glorikian has a track record of innovation and commercial success. His addition to the team is a very positive step forward for 3DS.”
Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. He has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets.
Mr. Glorikian is also author of the recently published and highly-relevant book, “Commercializing Novel IVDs: A Comprehensive Manual for Success.” An IVD is an in-vitro diagnostic device which is the type of diagnostic tool that 3DS is currently developing. Mr. Glorikian’s unique manual provides an overview of the major components to IVD development, from product conception through commercialization. His understanding of the diagnostic commercialization process in the context of clinical utility and cost effectiveness is an enormous asset to 3DS.
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 20 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.